Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68788-6806

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68788-6806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 01

A pharmacokinetic interaction chart for venlafaxine hydrochloride showing the fold changes in Cmax and AUC when administered with various interacting drugs including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The chart includes recommendations such as 'Avoid concomitant use' and 'No dose adjustment,' with a horizontal axis depicting change relative to the reference value.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 02

A forest plot graph titled 'PKFold Change and 90% CI' showing the pharmacokinetic changes of various interacting drugs with venlafaxine hydrochloride. The x-axis represents the change relative to the reference value, ranging from 0 to 3. Listed drugs include ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium, with corresponding Cmax and AUC analytes. The graph also includes clinical recommendations such as 'No dose adjustment,' 'Avoid concomitant use,' 'Clinical significance unknown,' and 'Use with caution, monitor blood pressure.'*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 03

A pharmacokinetic plot showing fold change and 90% confidence intervals for venlafaxine and its metabolite ODV across special populations including hepatic impairment, renal impairment, genetic polymorphisms, age, and gender. The chart assesses changes in Cmax and AUC relative to a reference value with dosage adjustment recommendations annotated for each population group.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 04

Chemical structure of venlafaxine hydrochloride, showing the molecular arrangement including a cyclohexane ring, phenyl ring with methoxy group, and a dimethylamino ethyl side chain, with hydrochloride salt indicated.*

FDA Label Image

E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 07

Label for venlafaxine hydrochloride extended-release capsules USP 150 mg, generic for Effexor ER. The label indicates oral capsules, extended release, with packaging and batch details to be filled, manufactured by Zydus Pharmaceuticals USA Inc. It includes directions for use in English and Spanish on a yellow background, with caution against drug transfer and a barcode on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.